## LRCX: Lam Research Corporation - XLK: Technology

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 6.0% in lower entry zone (4.0-10.0%), top quartile (80th pct) cross-sectional ranking. Short-term MRS_5 (0.8%) confirms momentum alignment. Outperforming sector by 6.4%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($150.86)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Lam Research (LRCX) Stock Is Up, What You Need To Know**
- Source: Finviz | 20251215T200828 | Somewhat-Bullish | Relevance: 100%
- Shares of Lam Research (NASDAQ:LRCX) jumped after a Jefferies analyst maintained a "Buy" rating and increased the price target to $200 from $175, reflecting confidence in the company's future growth. The stock saw a 3.2% rise initially, settling at $165.10, up 2.9% from its previous close. This positive movement follows a prior price target increase by Morgan Stanley and occurs amidst broad strength in the chip-making sector, with LRCX up 128% year-to-date.

**2. Farmers Trust Co. Purchases 13,136 Shares of Lam Research Corporation $LRCX**
- Source: MarketBeat | 20251215T101236 | Bullish | Relevance: 100%
- Farmers Trust Co. has increased its stake in Lam Research Corporation (NASDAQ:LRCX) by 30.1%, acquiring an additional 13,136 shares, bringing its total holdings to 56,710 shares valued at $7.59 million. This makes Lam Research the firm's 18th largest position, accounting for 1.3% of its portfolio. The semiconductor company recently beat Q3 earnings estimates and received several analyst target price increases, although insiders have been net sellers.

**3. Migdal Insurance & Financial Holdings Ltd. Decreases Stake in Lam Research Corporation $LRCX**
- Source: MarketBeat | 20251215T130748 | Neutral | Relevance: 100%
- Migdal Insurance & Financial Holdings Ltd. significantly reduced its stake in Lam Research Corporation (NASDAQ:LRCX) by 68.4% in the second quarter, selling 6,409 shares and retaining 2,958 shares valued at $288,000. Despite this decrease, other major institutional investors like Vanguard Group Inc., State Street Corp, JPMorgan Chase & Co., and Geode Capital Management LLC increased their positions in the semiconductor company. The article also notes recent analyst ratings, stock performance, and insider selling activities at Lam Research.

**4. Liontrust Investment Partners LLP Sells 137,311 Shares of Lam Research Corporation $LRCX**
- Source: MarketBeat | 20251215T112334 | Somewhat-Bullish | Relevance: 100%
- Liontrust Investment Partners LLP significantly reduced its stake in Lam Research Corporation (NASDAQ:LRCX) by 68.7%, selling 137,311 shares in Q2 and now holding 62,418 shares valued at $6.08 million. Despite this, other major institutions like Norges Bank and JPMorgan Chase & Co. have either initiated or substantially increased their positions, with institutional investors collectively owning 84.61% of the stock. Insider selling also occurred, while Lam Research reported strong Q3 earnings, beating EPS expectations, and declared a $0.26 quarterly dividend.

**5. Public Sector Pension Investment Board Sells 459,575 Shares of Lam Research Corporation $LRCX**
- Source: MarketBeat | 20251214T110809 | Neutral | Relevance: 100%
- The Public Sector Pension Investment Board reduced its stake in Lam Research Corporation by 54.6% in the second quarter, selling 459,575 shares and retaining 382,203 shares valued at $37.2 million. Despite this institutional sell-off, analysts largely maintain a "Moderate Buy" rating for Lam Research with a consensus target price of $152.87, following the company's beat on quarterly earnings estimates. Insider selling has also been noted, with CFO Douglas Bettinger selling over 40,000 shares, contributing to a total of 102,608 insider shares sold in the last 90 days.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Jefferies | $200 | $175 | +14% |
| 2025-12-02 | Morgan Stanley | $158 | $137 | +15% |
| 2025-11-25 | UBS | $175 | $165 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Jefferies | main | Buy |
| 2025-12-02 | Morgan Stanley | main | Equal-Weight |
| 2025-11-25 | UBS | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 11 ($0.00M) |
| Sells | 6 ($14.07M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 39.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.4% (+0.3%)
- Blackrock Inc.: 9.9% (+1.7%)
- JPMORGAN CHASE & CO: 4.8% (+47.4%)
- State Street Corpora: 4.8% (+0.4%)
- Geode Capital Manage: 2.7% (-0.5%)

### Key Risks

1. Heavy insider selling: $14M sold (6 transactions in 90 days).
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 3 raises (avg +12%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.99 elevated, pricing in significant growth expectations. Quality metrics strong (ROE 62%, ROA 20%, margin 30%). Balance sheet: strong liquidity (2.2x), $1.6B free cash flow. Analyst sentiment positive (3 raises, avg +12%). Insider selling cluster ($14.1M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $207.2B |
| Beta | 1.78 |
| 52W Range | $56.32 - $169.69 |
| Short Interest | 3.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.99 |
| Forward P/E | 29.3 |
| Current P/E | 33.9 |
| YoY Growth | 15.9% |
| EPS Direction | RISING |

### Technicals

MRS_20 stable at 6.0% (minimal 5-day change). Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 80th percentile. MRS_5 at 0.8% confirms short-term momentum alignment. AM_20 at 5.6% shows strong absolute momentum above own 20MA. Outperforming sector by 6.4pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.65), confirming momentum. RSI neutral at 58. OFD pattern: +SUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 5.96% (CS: 81) | Strong |
| RSI_14 | 57.7 | Neutral |
| MACD Histogram | 0.65 | Bullish |
| vs SMA20 | 1.055x | Above |
| vs SMA50 | 1.076x | Above |
| vs SMA200 | 1.538x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $164.30
- **Stop Loss:** $150.86 (8.2% risk)
- **Target:** $184.46 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 74
- **Position Value:** $12,158.20
- **Portfolio %:** 12.16%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-01-28 (Est: $1.16)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.22 | $1.26 | +3.3% |
| 2025Q2 | $1.21 | $1.33 | +10.4% |
| 2025Q1 | $1.00 | $1.04 | +4.1% |
| 2024Q4 | $0.88 | $0.91 | +3.5% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*